ライフサイエンスコーパス: adefovir dipivoxil

1 ts from 2 multinational phase III studies of adefovir dipivoxil.

2 on with amprenavir, abacavir, efavirenz, and adefovir dipivoxil.

3 ne offer greater potency than lamivudine and adefovir dipivoxil.

4 r 6 weeks, followed by 6 weeks of open-label adefovir dipivoxil.

5 d improvement in the liver/kidney ratio over adefovir dipivoxil.

6 f lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily.

7 treatment with lamivudine were randomized to adefovir dipivoxil 10 mg, lamivudine 100 mg, or addition

8 Forty-eight weeks of adefovir dipivoxil 10-mg therapy resulted in potent redu

9 Antiviral efficacy of adefovir dipivoxil 10-mg therapy was examined with respe

10 ques, only 1 of the 24 subjects who received adefovir dipivoxil (125 mg/day) developed any genotypic

11 Adefovir dipivoxil [9-(2-(bispivaloyloxymethyl)phosphony

12 We have found that adefovir dipivoxil, a drug approved to treat chronic inf

13 Adefovir dipivoxil, a marketed drug for the treatment of

14 Adefovir dipivoxil, a prototype phosphonate analog, has

15 eived 48 weeks of TDF 300 mg (HVL n = 82) or adefovir dipivoxil (ADV) 10 mg (HVL n = 47), followed by

16 Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment

17 Adefovir dipivoxil (ADV) has demonstrated clinical activ

18 he efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents wit

19 susceptibility to, and treatment failure of, adefovir dipivoxil (ADV).

20 fter long-term (4 or 5 years) treatment with adefovir dipivoxil (ADV).

21 n has been reported in patients treated with adefovir dipivoxil (ADV); however, its incidence and cli

22 e randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks.

23 is study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivud

24 ith compensated liver disease, indicate that adefovir dipivoxil alone or in combination with ongoing

25 placebo-controlled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was con

26 C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-mediated activatio

27 This study provides evidence that adefovir dipivoxil can be an effective treatment for lam

28 received placebo or one of three dosages of adefovir dipivoxil daily for 14 days.

29 el were seen by 4 weeks in all recipients of adefovir dipivoxil; DAVG(16) was -0.07 in the lamivudine

30 After 14 days of dosing, adefovir dipivoxil demonstrated anti-HIV activity and wa

31 s enrolled in a phase I/II clinical trial of adefovir dipivoxil demonstrated that the K70E RT mutatio

32 B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1-l

33 % of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resis

34 mivudine, adefovir dipivoxil/lamivudine, and adefovir dipivoxil groups, respectively.

35 Adefovir dipivoxil has a superior first line resistance

36 The patients were treated with adefovir dipivoxil in a dose of 5 to 30 mg daily.

37 ment-related adverse effects associated with adefovir dipivoxil in this setting were primarily mild t

38 (PMEApp), the active cellular metabolite of adefovir dipivoxil, inhibits the adenylyl cyclase activi

39 Adefovir dipivoxil is a clinically approved drug that ca

40 Adefovir dipivoxil is a novel nucleotide analogue with s

41 Adefovir dipivoxil is a nucleotide analog that has demon

42 Adefovir dipivoxil is a promising new treatment for lami

43 d adults evaluated once-daily treatment with adefovir dipivoxil, lamivudine, didanosine, and efaviren

44 ith -2.45 and -2.46 log(10) copies/mL in the adefovir dipivoxil/lamivudine and adefovir dipivoxil mon

45 of 19 (53%) and 9 of 18 (47%) recipients of adefovir dipivoxil/lamivudine and adefovir dipivoxil, re

46 ree patients receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and none receiving lamivud

47 d -4.04 log(10) copies/mL in the lamivudine, adefovir dipivoxil/lamivudine, and adefovir dipivoxil gr

48 /mL in the adefovir dipivoxil/lamivudine and adefovir dipivoxil monotherapy groups, respectively (P <

49 To evaluate the safety and efficacy of adefovir dipivoxil monotherapy, a randomized, double-bli

50 to receive either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable pla

51 Three patients receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and

52 randomly assigned in a 2:1 ratio to receive adefovir dipivoxil or placebo as a once-daily oral dose

53 Adefovir dipivoxil possesses potent in vitro and in vivo

54 ipients of adefovir dipivoxil/lamivudine and adefovir dipivoxil, respectively, compared with 1 of 19

55 In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements

56 1 RNA levels were significantly greater with adefovir dipivoxil than with placebo.

57 Forty-eight weeks of adefovir dipivoxil therapy resulted in significant decre

58 anscriptase (RT) potentially attributable to adefovir dipivoxil therapy.

59 vudine resistance mutations may benefit from adefovir dipivoxil therapy.

60 evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with ch

61 The addition of adefovir dipivoxil to lamivudine in patients with CHB wi

62 xil 10 mg, lamivudine 100 mg, or addition of adefovir dipivoxil to ongoing lamivudine daily.

63 In a phase II study of 6-12 months of adefovir dipivoxil treatment in human immunodeficiency v

64 Adefovir dipivoxil was determined to be safe and well-to

65 Adefovir dipivoxil was safe and effective for treatment-

66 Hepatitis B immunoglobulin and adefovir dipivoxil were initiated.